個別化医療の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2025年～2033年

個別化医療市場の概要

世界の個別化医療市場規模は2024年に5,671億米ドルと推定され、2033年には1兆1,961億8,000万米ドルに達すると予測され、2025～2033年のCAGRは8.80%で成長します。標的治療と精密診断に対する需要の高まりが、個別化医療市場の拡大を大きく後押ししています。

ゲノム技術、バイオマーカー同定、データ駆動型治療戦略の進歩により、ヘルスケア提供者は個々の患者プロファイルに合わせた治療を行うことができます。このアプローチは治療効果を高め、副作用を最小限に抑え、ヘルスケア資源の効率的な利用をサポートします。慢性疾患や複雑な疾患が世界的に増加する中、個別化ソリューションへの注目は強まり続け、診断、治療、健康データ統合プラットフォームにわたる革新と投資が促進されています。がん、糖尿病、心血管疾患などの慢性疾患の増加は、ヘルスケア提供者に個別化治療戦略の実施を促しています。

個別化診断は、より高い精度で病気を特定し、早期介入と臨床転帰の改善につながります。2024年、IlluminaがFDAに承認されたTruSight Oncology Comprehensive検査が500以上の遺伝子を分析し、標的となるがん治療の指針となったように、個別化診断は疾患の特定においてより高い精度をもたらしました。遺伝的素因に対する患者の意識の高まりが、DNAベース検査サービスの普及を支えています。プロアクティブで患者に特化したケアモデルを目指すこの動きは、医療領域全体にわたって市場の可能性を拡大し続けています。

ゲノミクス、人工知能、データ分析の技術的進歩は、個別化医療市場の成長をさらに促進します。企業開発は、次世代シーケンサー、バイオマーカー探索、バイオインフォマティクスを活用して、個々の患者プロファイルに合わせた革新的なソリューションを開発しています。臨床上の意思決定へのAIの統合により、複雑なデータセットの迅速な分析が可能になり、診断の精度や治療法の選択が強化されています。遠隔医療プラットフォームと医療ITシステムは、特に慢性疾患管理において、個別化ケアへの遠隔アクセスを容易にします。こうした技術革新はヘルスケアの提供を再形成し、カスタマイズ型アプローチのスケーラブルな導入を支えています。

民間セクタの投資や戦略的提携の増加も、市場の勢いに寄与しています。製薬会社は診断薬企業と提携し、標的治療のコンパニオン診断薬を共同開発しています。新興企業やバイオテクノロジー企業は、革新的な栄養、ウェルネス、ゲノミクス製品を提供して市場に参入しています。健康の最適化や予防医療に対する消費者の関心の高まりは、消費者直接検査やカスタマイズ型ウェルネスプランへの需要を後押ししています。市場競合を強化するため、各社は製品の差別化、データ主導の戦略、世界展開に注力しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 個別化医療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 個別化医療市場：製品ビジネス分析

• 製品市場シェア、2024年と2033年
• 製品セグメントダッシュボード
• 市場規模と予測と動向分析（製品別、2021～2033年）
• 個別化医療診断
• 個別化医療治療
• 個別化医療
• 個別化栄養・健康

第5章 個別化医療市場：最終用途ビジネス分析

• 最終用途市場シェア、2024年と2033年
• 最終用途セグメントダッシュボード
• 市場規模、予測、動向分析（最終用途別、2021～2033年）
• 病院
• 診断センター
• 研究・学術機関
• その他

第6章 個別化医療市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2033年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2021～2033年
• 北米
  • 国別、2021～2033年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation（Cepheid, Inc.）
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation（IBM）
  • Genentech, Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Personalized medicine market, by region, 2021 - 2033 (USD Million)
• Table 4 Global Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 5 Global Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 6 North America Personalized medicine market, by country, 2021 - 2033 (USD Million)
• Table 7 North America Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 8 North America Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 9 U.S. Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 10 U.S. Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 11 Canada Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 12 Canada Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 13 Mexico Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 14 Mexico Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 15 Europe Personalized medicine market, by country, 2021 - 2033 (USD Million)
• Table 16 Europe Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 17 Europe Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 18 UK Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 19 UK Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 20 Germany Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 21 Germany Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 22 France Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 23 France Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 24 Italy Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 25 Italy Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 26 Spain Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 27 Spain Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 28 Norway Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 29 Norway Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 30 Denmark Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 31 Denmark Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 32 Sweden Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 33 Sweden Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 34 Asia Pacific Personalized medicine market, by country, 2021 - 2033 (USD Million)
• Table 35 Asia Pacific Personalized medicine market, by product, 2021 - 2033 (USD
• Table 36 Asia Pacific Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 37 Japan Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 38 Japan Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 39 China Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 40 China Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 41 India Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 42 India Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 43 Australia Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 44 Australia Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 45 South Korea Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 46 South Korea Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 47 Thailand Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 48 Thailand Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 49 Latin America Personalized medicine market, by country, 2021 - 2033 (USD Million)
• Table 50 Latin America Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 51 Latin America Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 52 Brazil Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 53 Brazil Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 54 Argentina Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 55 Argentina Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 56 Middle East & Africa Personalized medicine market, by country, 2021 - 2033 (USD Million)
• Table 57 Middle East & Africa Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 58 Middle East & Africa Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 59 South Africa Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 60 South Africa Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 61 Saudi Arabia Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 62 Saudi Arabia Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 63 UAE Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 64 UAE Personalized medicine market, by end use, 2021 - 2033 (USD Million)
• Table 65 Kuwait Personalized medicine market, by product, 2021 - 2033 (USD Million)
• Table 66 Kuwait Personalized medicine market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Personalized medicine market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Personalized medicine market dynamics
• Fig. 12 Personalized medicine market: Porter's five forces analysis
• Fig. 13 Personalized medicine market: PESTLE analysis
• Fig. 14 Product market, 2021 - 2033 (USD Million)
• Fig. 15 Personalized medicine diagnostics market, 2021 - 2033 (USD Million)
• Fig. 16 Genetic testing market, 2021 - 2033 (USD Million)
• Fig. 17 Direct-To-Consumer (DTC) Diagnostics market, 2021 - 2033 (USD Million)
• Fig. 18 Esoteric lab services market, 2021 - 2033 (USD Million)
• Fig. 19 Esoteric lab tests market, 2021 - 2033 (USD Million)
• Fig. 20 Personalized medicine therapeutics market, 2021 - 2033 (USD Million)
• Fig. 21 Pharmaceutical market, 2021 - 2033 (USD Million)
• Fig. 22 Genomic medicine market, 2021 - 2033 (USD Million)
• Fig. 23 Medical devices market, 2021 - 2033 (USD Million)
• Fig. 24 Personalized medical care market, 2021 - 2033 (USD Million)
• Fig. 25 Telemedicine market, 2021 - 2033 (USD Million)
• Fig. 26 Health information technology market, 2021 - 2033 (USD Million)
• Fig. 27 Personalized nutrition & wellness market, 2021 - 2033 (USD Million)
• Fig. 28 Retail nutrition market, 2021 - 2033 (USD Million)
• Fig. 29 Complementary & alternative medicine market, 2021 - 2033 (USD Million)
• Fig. 30 End use market, 2021 - 2033 (USD Million)
• Fig. 31 Hospitals market, 2021 - 2033 (USD Million)
• Fig. 32 Diagnostic centers market, 2021 - 2033 (USD Million)
• Fig. 33 Research & academic institutes market, 2021 - 2033 (USD Million)
• Fig. 34 Others market, 2021 - 2033 (USD Million)
• Fig. 35 Personalized medicine market revenue, by region
• Fig. 36 Regional marketplace: Key takeaways
• Fig. 37 North America Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 38 U.S. country dynamics
• Fig. 39 U.S. Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 40 Canada country dynamics
• Fig. 41 Canada Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 42 Mexico country dynamics
• Fig. 43 Mexico Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 44 Europe Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 45 UK country dynamics
• Fig. 46 UK Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 47 Germany country dynamics
• Fig. 48 Germany Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 49 France country dynamics
• Fig. 50 France Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 51 Italy country dynamics
• Fig. 52 Italy Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 53 Spain country dynamics
• Fig. 54 Spain Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 55 Norway country dynamics
• Fig. 56 Norway Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 57 Sweden country dynamics
• Fig. 58 Sweden Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 59 Denmark country dynamics
• Fig. 60 Denmark Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 61 Asia Pacific Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 62 Japan country dynamics
• Fig. 63 Japan Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 64 China country dynamics
• Fig. 65 China Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 66 India country dynamics
• Fig. 67 India Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 68 Australia country dynamics
• Fig. 69 Australia Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 70 South Korea country dynamics
• Fig. 71 South Korea Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 72 Thailand country dynamics
• Fig. 73 Thailand Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 74 Latin America Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 75 Brazil country dynamics
• Fig. 76 Brazil Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 77 Argentina country dynamics
• Fig. 78 Argentina Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 79 MEA Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 80 South Africa country dynamics
• Fig. 81 South Africa Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 82 Saudi Arabia country dynamics
• Fig. 83 Saudi Arabia Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 84 UAE country dynamics
• Fig. 85 UAE Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 86 Kuwait country dynamics
• Fig. 87 Kuwait Personalized medicine market, 2021 - 2033 (USD Million)
• Fig. 88 Company categorization
• Fig. 89 Company market position analysis
• Fig. 90 Strategic framework

Personalized Medicine Market Summary

The global personalized medicine market size was estimated at USD 567.10 billion in 2024 and is projected to reach USD 1,196.18 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The growing demand for targeted therapies and precision diagnostics is significantly driving the expansion of the personalized medicine market.

Advances in genomic technologies, biomarker identification, and data-driven treatment strategies enable healthcare providers to tailor therapies to individual patient profiles. This approach enhances treatment efficacy, minimizes adverse effects, and supports more efficient use of healthcare resources. As chronic and complex diseases rise globally, the focus on personalized solutions continues to strengthen, fostering innovation and investment across diagnostics, therapeutics, and health data integration platforms. The rise in chronic conditions such as cancer, diabetes, and cardiovascular diseases is prompting healthcare providers to implement individualized treatment strategies.

Personalized diagnostics deliver greater accuracy in disease identification, leading to earlier intervention and better clinical outcomes. Personalized diagnostics delivered greater accuracy in disease identification, as in 2024 when Illumina's FDA approved TruSight Oncology Comprehensive test analyzed over 500 genes to guide targeted cancer treatments. The increasing awareness among patients of genetic predispositions supports the uptake of DNA-based testing services. This movement toward proactive, patient-specific care models continues to expand the market's potential across medical domains.

Technological advancements in genomics, artificial intelligence, and data analytics further fuel growth in the personalized medicine market. Companies are leveraging next-generation sequencing, biomarker discovery, and bioinformatics to develop innovative solutions tailored to individual patient profiles. AI integration into clinical decision-making is enabling faster analysis of complex datasets, enhancing diagnostic precision and therapy selection. Telemedicine platforms and health IT systems facilitate remote access to personalized care, especially in chronic disease management. These technological innovations are reshaping healthcare delivery and supporting the scalable adoption of customized approaches.

Increasing private sector investments and strategic collaborations are also contributing to market momentum. Pharmaceutical companies are partnering with diagnostics firms to co-develop companion diagnostics for targeted therapies. Startups and biotech firms are entering the market with innovative nutrition, wellness, and genomics offerings. Expanding consumer interest in health optimization and preventive care is boosting demand for direct-to-consumer testing and customized wellness plans. Market players focus on product differentiation, data-driven strategies, and global expansion to strengthen their competitive positions.

Global Personalized Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global personalized medicine market report based on product, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Personalized Medicine Diagnostics
  • Genetic Testing
  • Direct-To-Consumer (DTC) Diagnostics
  • Esoteric Lab Services
  • Esoteric Lab Tests
• Personalized Medicine Therapeutics
  • Pharmaceutical
  • Genomic Medicine
  • Medical Devices
• Personalized Medical Care
  • Telemedicine
  • Health Information Technology
• Personalized Nutrition & Wellness
  • Retail Nutrition
  • Complementary & Alternative Medicine
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Personalized Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Personalized Medicine Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Personalized Medicine Diagnostics
  • 4.4.1. Personalized Medicine Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.4.2. Genetic Testing
    • 4.4.2.1. Genetic Testing Market, 2021 - 2033 (USD Million)
  • 4.4.3. Direct-To-Consumer (DTC) Diagnostics
    • 4.4.3.1. Direct-To-Consumer (DTC) Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.4.4. Esoteric Lab Services
    • 4.4.4.1. Esoteric Lab Services Market, 2021 - 2033 (USD Million)
  • 4.4.5. Esoteric Lab Tests
    • 4.4.5.1. Esoteric Lab Tests Market, 2021 - 2033 (USD Million)
• 4.5. Personalized Medicine Therapeutics
  • 4.5.1. Personalized Medicine Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.5.2. Pharmaceutical
    • 4.5.2.1. Pharmaceutical Market, 2021 - 2033 (USD Million)
  • 4.5.3. Genomic Medicine
    • 4.5.3.1. Genomic Medicine Market, 2021 - 2033 (USD Million)
  • 4.5.4. Medical Devices
    • 4.5.4.1. Medical Devices Market, 2021 - 2033 (USD Million)
• 4.6. Personalized Medical Care
  • 4.6.1. Personalized Medical Care Market, 2021 - 2033 (USD Million)
  • 4.6.2. Telemedicine
    • 4.6.2.1. Telemedicine Market, 2021 - 2033 (USD Million)
  • 4.6.3. Health Information Technology
    • 4.6.3.1. Health Information Technology Market, 2021 - 2033 (USD Million)
• 4.7. Personalized Nutrition & Wellness
  • 4.7.1. Personalized Nutrition & Wellness Market, 2021 - 2033 (USD Million)
  • 4.7.2. Retail Nutrition
    • 4.7.2.1. Retail Nutrition Market, 2021 - 2033 (USD Million)
  • 4.7.3. Complementary & Alternative Medicine
    • 4.7.3.1. Complementary & Alternative Medicine Market, 2021 - 2033 (USD Million)

Chapter 5. Personalized Medicine Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.5. Diagnostic Centers
  • 5.5.1. Diagnostic Centers Market, 2021 - 2033 (USD Million)
• 5.6. Research & Academic Institutes
  • 5.6.1. Research & Academic Institutes Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Personalized Medicine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. End Use Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. End Use Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. End Use Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. End Use Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. End Use Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. End Use Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. End Use Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. End Use Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. End Use Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. End Use Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. End Use Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. End Use Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. End Use Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. End Use Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. End Use Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. End Use Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. End Use Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. End Use Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. End Use Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. End Use Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. End Use Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. End Use Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. End Use Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. GE Healthcare
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Illumina, Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. ASURAGEN, INC.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Abbott
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Dako A/S
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Exact Sciences Corporation
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Danaher Corporation (Cepheid, Inc.)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Decode Genetics, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. QIAGEN
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Exagen Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Precision Biologics
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Celera Diagnostics LLC.
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
  • 7.5.13. Biogen
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
  • 7.5.14. Genelex
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
  • 7.5.15. International Business Machines Corporation (IBM)
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
  • 7.5.16. Genentech, Inc.
    • 7.5.16.1. Overview
    • 7.5.16.2. Financial Performance
    • 7.5.16.3. Product Benchmarking